Vitrolife Ab · OMXSTO:VITR
Vitrolife Ab — Q3 2025 Earnings Presentation
10 slides from Vitrolife Ab's earnings presentation, 2025
Slide 1: Pre-silent call prior to Q3 2025
Vitrolife AB (publ) Pre-silent call prior to Q3 2025 Bronwyn Brophy O'Connor, CEO Helena Wennerström, Acting CFO Amelie Wilson, Investor relations, external corporate communications and executive support
Slide 2: Key factors to consider in Q3 2025 compared to Q3 2024
Key factors to consider in Q3 2025 compared to Q3 2024 1. Strong growth comparison due to media share gain throughout 2024 2. IVF Executive order 3. APAC cycle growth Strong sales in Consumables Still no update from the White Very little signs of recovery in with 13% growth in Q3 2024. house. Asia.
Slide 3: 1. Strong growth comparison due to media share gain throughout 2024
1. Strong growth comparison due to media share gain throughout 2024 3
Slide 4: 2. Impact of IVF Executive Order on cycles in the US in Q3 2025
2. Impact of IVF Executive Order on cycles in the US in Q3 2025 “Within 90 days of the date of this order, the Assistant to the President for Domestic Policy shall submit to the President a list of policy recommendations on protecting IVF access and aggressively reducing out-of-pocket and health pla
Slide 5: 3. APAC cycle growth
3. APAC cycle growth • Chinese REI's and academics are reporting that China's one child policy (150 million one child families today) has impacted people's desire and ability to have children. • Despite changes to reimbursement policy in China, with a shift in the site of care out to the provinces p
Slide 6: Currency headwinds during H1 2025 continues into Q3
Currency headwinds during H1 2025 continues into Q3 Currency, development YTD 2025 Net transaction exposure is allocated over the following currencies Vitrolife Group’s transaction exposure risk is attributable to income and Vitrolife Group’s translation exposure risk is attributable to net investme
Slide 7: Focus for 2025
Focus for 2025 Continue to drive share gain in key markets leveraging the full breadth of the portfolio. Growth Accelerate penetration of our combined EmbryoScope and lab control solutions. Deliver best in class quality and customer service to further differentiate from competitors. Prioriti
Slide 8: Reasons to invest in Vitrolife AB (publ)
Reasons to invest in Vitrolife AB (publ) • Underlying resilient market growth. • High quality brands linked with outstanding service and support. • Proven track record of profitable growth. • Innovation and technology leader within fertility. • Ambitious strategy and long-term objectives. Contact: in
Slide 9: Tariff update as of September 2025
Appendix Tariff update as of September 2025 Current status: • US: End of July, The US and EU have reached a deal on trade tariffs which sets a 15% tariff for import into the US, effective from August 1st. The political agreement for this deal is not legally binding and may be subject to further nego
Slide 10: Disclaimer
Disclaimer This presentation may contain estimates and forward-looking statements, which reflect the Management’s current views with respect to the market, certain future events and financial performance. Although the statements are based upon estimates the Management believes to be reasonable, there